Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide (cas 460738-38-9), a novel kallikrein inhibitor

Add time:07/18/2019    Source:sciencedirect.com

BackgroundHereditary angioedema (HAE) is a rare, autosomal-dominant disorder caused by C1 inhibitor gene mutation. Patients with HAE experience intermittent attacks of edema affecting the oropharynx, abdomen, gastrointestinal tract, and limbs. C1 inhibitor is the primary endogenous inhibitor of the kallikrein-kinin (contact) cascade. Unregulated kallikrein activation generates bradykinin, the likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is the first placebo-controlled assessment in human beings of a therapeutic intervention to improve symptoms of HAE attacks under the hypothesis that the contact cascade is the putative pathway responsible for HAE pathology.

We also recommend Trading Suppliers and Manufacturers of ecallantide (cas 460738-38-9). Pls Click Website Link as below: cas 460738-38-9 suppliers

Prev:ecallantide (cas 460738-38-9) (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies
Next:Synthesis of three branched iminosugars [(3R,4R,5S)-3-(hydroxymethyl)piperidine-3,4,5-triol, (3R,4R,5R)-3-(hydroxymethyl)piperidine-3,4,5-triol and (3S,4R,5R)-3-(hydroxymethyl)piperidine-3,4,5-triol] and a branched trihydroxynipecotic acid [(3R,4R,5R)-3,4,5-trihydroxypiperidine-3-carboxylic acid] from sugar lactones with a carbon substituent at C-2)